Here’s what’s in store for you in today’s issue:
🍄 Canadian Senator microdoses for depression
🍄 MindMed’s ibogaine study results
🍄 Yale to study psilocybin for OCD
🍄 Ketamine for gaming addiction 🎮
🍄 And more.
Listen now on YouTube, Spotify, or Apple
After piloting the program for 9 months, Novamind’s group ketamine therapy for frontline workers is now available to the public.
The 6-week program is designed to help healthcare workers, police officers, firefighters and paramedics work through trauma with the support of their peers.
“The greatest improvement has been my PTSD… Even when I do feel myself reacting, I feel I have more awareness and I am able to better regulate,” says one of the participants of the pilot program.
This quarter, MindMed (MNMD) will begin a Phase 2a trial to see if its non-hallucinogenic ibogaine formulation (MM-110) can treat opioid withdrawal.
In preclinical research, MM-110 showed “multi-day reductions in opioid self-administration” after a single dose.
In the Phase 1 trial, MM-110 was found to be safe and well-tolerated at varying doses. Some participants received two 325 mg doses on a single day while others received a 90 mg dose twice daily for 7 days.
Let’s see what Phase 2 reveals!
Ceruvia Lifesciences submitted an application to study psilocybin as a treatment for obsessive-compulsive disorder (OCD) in a Phase 2 trial.
Preliminary findings suggest that psilocybin causes a “rapid and robust improvement in OCD symptoms with a sustained effect,” according to the press release.
The trial, which will be led by Yale researchers later this year if approval is granted, will determine if these findings hold true when psilocybin is compared to an active placebo.
Collectively, over a billion people struggle with Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder, and Compulsive Sexual Behaviour.
Researchers at Awakn Life Sciences (AWKN) completed the world’s first ketamine study for these behavioural addictions. The results were “hugely encouraging,” according to the CEO.
While actual data is yet to be released, the promising early findings “merit a larger study and further exploration,” which the company is now pursuing.
Silo Pharma (SILO) began a trial to see if psilocybin can reduce inflammation in patients with signs of Parkinson’s disease.
Beckley Psytech will be using Empatica’s wearable biomarker devices in a 5-MeO-DMT study for treatment resistant depression. The devices will gather behavioural and physiological data with the goal of identifying early signals of patient response and relapse.
Braxia Scientific (BRAX) received Health Canada approval to administer psilocybin therapy for depression through the Special Access Program.
CB Therapeutics was granted a patent for an “eco-conscious” psilocybin production method involving precision fermentation.
PharmaTher (PHRM) is partnering with CC Biotechnology to develop a wearable ketamine delivery device for mental health, chronic pain, and neurological disorders.
The Oregon Health Authority has finalized the first subset of rules for the legal psilocybin services that will be available next year.
The full set of guideline, which cover psilocybin production methods and facilitator training requirements, can be found here.
A second committee meeting will take place in the Fall to establish the remainder of the rules.